

ADVERTISEMENT | Regulated information

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR TO US PERSONS (AS DEFINED IN REGULATION S UNDER THE US SECURITIES ACT OF 1933, AS AMENDED), AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.

87.7% of new shares subscribed at closing of the rights subscription period for holders of preferential rights

Sale of the scrips through a private placement to qualified investors to start today

Brussels, 3 October 2025, 9:15 a.m. CET – Sofina SA (“Sofina” or the “Company”) announces today that 2,145,418 new shares or 87.7% of the up to 2,446,428 new shares it offered as part of its rights offering for a maximum amount of c. €545 million (including issue premium) were subscribed at a subscription price of €223.00 per new share, on the basis of 1 new share for 14 extra-legal preferential rights. The rights subscription period with preferential rights closed on 2 October 2025 at 4 p.m. CET. The sale of the Scrips through a private placement to qualified investors starts today.

The 4,214,148 extra-legal preferential rights, represented by coupon nr. 28, which were not exercised at the end of the rights subscription period, including the 1,149,306 extra-legal preferential rights corresponding to the Company's treasury shares upon the detachment of coupon nr. 28, have been converted into an equal number of scrips (the “Scrips”). The Scrips will be offered for sale in a private placement to qualified investors (the “Scrips Private Placement”). This sale will take place today and is expected to end today.

The net proceeds of the sale of Scrips (rounded down to a whole eurocent per unexercised extra-legal preferential right) after deducting expenses, charges and all forms of expenditure which the Company has to incur for the sale of the Scrips (if any) will be distributed proportionally between all holders of extra-legal preferential rights who did not exercise such rights, unless the net proceeds from the sale of the Scrips divided by the total number of unexercised extra-legal preferential rights is less than €0.01, in which case the net proceeds will be transferred to the Company.

Purchasers of Scrips in the Scrips Private Placement will irrevocably undertake to subscribe to the corresponding number of new shares in Sofina at €223.00 per new share in the ratio of 1 new share for 14 extra-legal preferential rights under the form of Scrips.

The result of the Scrips Private Placement, the global results of the rights offering and the amount due to holders of unexercised preferential rights (if any) are due to be announced in a press release later today, which will be available on www.sofinagroup.com/capital-increase-2025/. At the request of the Company, the trading of its shares on the regulated market of Euronext in Brussels (“Euronext Brussels”) has been suspended until the publication of such press release expected to be made later today.

The delivery of the new shares is expected to take place with the value date of 7 October 2025. The new shares will in principle be tradable on Euronext Brussels from the same date.

Additional information, subject to applicable legal restrictions, is available here: www.sofinagroup.com/capital-increase-2025/

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR TO US PERSONS (AS DEFINED IN REGULATION S UNDER THE US SECURITIES ACT OF 1933, AS AMENDED), AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.

ADVERTISEMENT

Press release dated 3 October 2025 | Regulated Information

WARNING

Investing in the new shares involves significant risks. A prospective investor must consider, when taking its investment decision, that it may lose all or part of its investment. Investors should read the entire prospectus available on Sofina's website (www.sofinagroup.com/capital-increase-2025/) and, in particular, Chapter 1, "*Risk Factors*" beginning on page 9 of the Prospectus for a description of the material risks that should be carefully considered before subscribing for the new shares. Within each (sub)category of risk factors, the risks estimated to be the most material are presented first. All of these risk factors should be considered before investing in the new shares or the scrips. Specifically, prospective investors should be aware that: (i) Sofina's strategy may be unsuccessful or fail to achieve its intended results, which could negatively impact the overall investment performance and return of Sofina's portfolio and cause its share price to decline; (ii) the valuation models and methodologies used by Sofina for a significant majority of its investments involve judgment and assumptions, and the fair value of these investments may be incorrect and/or differ from their potential divestment value, which may impact the overall value of Sofina's portfolio in transparency and cause its share price to decline; (iii) Sofina's portfolio companies may face failures in their internal control systems, have poor governance practices, experience accounting, compliance or fraud-related issues, and be subject to negative media coverage in relation thereto, which may impact the overall value of Sofina's portfolio in transparency, damage Sofina's reputation and cause its share price to decline; and (iv) adverse stock market fluctuations, or Sofina's failure to anticipate and react to a mismatch between market and fundamental value of its portfolio, may have an adverse impact on Sofina's portfolio and, indirectly, on its share price.

The Belgian Financial Services and Markets Authority (the "FSMA") approved the prospectus prepared by Sofina on 23 September 2025. The FSMA only approves the Prospectus (including the summary of the Prospectus) as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation. Such approval should not be considered as an endorsement of the Company and of the quality of the new shares. Investors should make their own assessment of the suitability of investing in new shares. The approval of the Prospectus by the FSMA can in no way be considered as an endorsement of the valuation of Sofina's portfolio companies or the valuation methodologies used by Sofina.

Company profile

Sofina is Belgian investment company, listed on Euronext Brussels. Sofina's mission is to partner with leading entrepreneurs and families, backing them with patient capital and supportive advice to foster sustainable growth of their businesses. Relationships and alignment are at the heart of what we do. Sofina has investments in Europe, Asia and the United States in various sectors, with a particular focus on Consumer and retail, Digital transformation, Education, Healthcare and life sciences as well as Sustainable supply chains. For more information, please visit www.sofinagroup.com

Investors, analysts and media contact

Dirk Delmartino, Head of Communications
Mob: +32 470 61 49 65 – E-mail: dirk.delmartino@sofinagroup.com
Tel.: +32 2 551 06 11 – E-mail: info@sofinagroup.com

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR TO US PERSONS (AS DEFINED IN REGULATION S UNDER THE US SECURITIES ACT OF 1933, AS AMENDED), AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.

ADVERTISEMENT

Press release dated 3 October 2025 | Regulated Information

IMPORTANT INFORMATION

This press release is an advertisement and not a prospectus within the meaning of Regulation (EU) 2017/1129 as amended (the "Prospectus Regulation") or Regulation (EU) 2017/1129 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended (the "UK Prospectus Regulation"). This press release does not constitute a prospectus.

The new shares, the preferential rights and the Scrips have not and will not be registered under the securities laws of any jurisdiction other than Belgium. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the new shares, preferential rights or Scrips in any jurisdiction or to any person to whom it would be unlawful to make such an offer. Distribution of this press release and the offering and delivery of the new shares, the preferential rights or the Scrips may, in certain jurisdictions, be subject to specific regulations or restrictions. In particular, neither this press release, nor any part of it may be distributed, directly or indirectly, in the United States, Australia, Canada, Japan or South Africa. Persons in possession of s press release are urged to inform themselves of any such restrictions which may apply in their jurisdiction and to observe them. Any failure to comply with these restrictions may constitute a violation of the securities laws of that jurisdiction. The Company disclaims all responsibility for any violation of such restrictions by any person.

Neither the new shares, nor the preferential rights or the Scrips have been, or will be, registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or with any securities regulatory authority of any state or other jurisdiction of the United States, and they may not be offered, sold, pledged, delivered or otherwise transferred, directly or indirectly, in or into the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. In addition, the Company has not been and will not be registered under the U. S. Investment Company Act of 1940, as amended (the "U.S. Investment Company Act"). Accordingly, the new shares, the preferential rights and the Scrips may only be offered outside the United States in "offshore transactions" to non-"U.S. Persons" as defined in, and in accordance with, Regulation S under the U.S. Securities Act.

The Company has not authorized any offer to the public of new shares, preferential rights or Scrips in any Member state of the European Economic Area ("EEA") ("EEA Member State") other than Belgium. No action has been undertaken or will be undertaken to make an offer to the public of new shares, preferential rights or Scrips requiring a publication of a prospectus in any EEA Member State pursuant to the Prospectus Regulation. As a result, the new shares, preferential rights or Scrips may only be offered in an EEA Member State under the following exemptions of the Prospectus Regulation to any legal entity that is a qualified investor in the EEA as defined under Article 2(e) of the Prospectus Regulation in accordance with Article 1(4)(a) of the Prospectus Regulation.

In any EEA Member State other than Belgium, this press release is only addressed to and are only directed at persons EEA Member State who are "qualified investors" within the meaning of Article 2 (e) of the Prospectus Regulation and no person that is not a qualified investor may act or rely on this communication or any of its contents. In addition, this press release is only addressed to and directed at persons in the United Kingdom (the "UK") who are "qualified investors" within the meaning of Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("EUWA") (the "UK Prospectus Regulation"). This press release has been prepared on the basis that any offer in the UK will be made pursuant to an exemption under the UK Prospectus Regulation from the requirement to publish a prospectus for the Offering. In addition, in the UK, this press release is only being distributed to and are directed solely at (i) persons who are outside the United Kingdom; (ii) investment professionals falling within the meaning of Article 19(5) of the UK FSMA, (Financial Promotion) Order 2005, as amended (the "Order"); or (iii) high net worth entities and other persons to whom such communication may otherwise lawfully be made falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "Relevant Persons"). This press release is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

Neither the Company nor the Underwriters have authorized, nor do the Company or the Underwriters authorize, the making of any offer of new shares, preferential rights and Scrips through any financial intermediary, other than offers made by the Underwriters which constitute the final placement of the new shares, the preferential rights and the Scrips contemplated in the Prospectus.

Certain statements contained in this press release may be forward-looking statements, including, but not limited to, statements that are predictions of or indicate future events, trends, plans, expectations or objectives. As a general matter, statements contained herein other than statements of historical facts are, or may be deemed to be, forward-looking statements. Undue reliance should not be placed on forward-looking statements because, by their nature, they are

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR TO US PERSONS (AS DEFINED IN REGULATION S UNDER THE US SECURITIES ACT OF 1933, AS AMENDED), AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.

ADVERTISEMENT

Press release dated 3 October 2025 | Regulated Information

subject to known and unknown risks and uncertainties and can be affected by other factors that could cause Sofina's actual results to differ materially from those expressed or implied in such forward-looking statements. Please refer to Chapter 1, "*Risk Factors*" of the Prospectus for a description of certain important factors, risks and uncertainties that may affect Sofina's investments, businesses, Net Asset Value, financial performance and results of operations. Such forward-looking statements are made as of the date of this press release.

The information contained in this press release is of an indicative nature and has not been verified independently. No representation or warranty, whether express or implied, is given by or on behalf of the Company or by BNP Paribas Fortis SA/NV and Morgan Stanley & Co. International plc, as joint global coordinators (the "Joint Global Coordinators") or any of their respective affiliates regarding the accuracy, completeness or comprehensiveness or accuracy of the information and opinions contained in this press release. This press release is not meant to serve as a basis for, and shall not be used in connection with, an investment decision.